RenovoRx, Inc. Profile Avatar - Palmy Investing

RenovoRx, Inc.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath …

Biotechnology
US, Los Altos [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

RenovoRx, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of RNXT's Analysis
CIK: 1574094 CUSIP: 75989R107 ISIN: US75989R1077 LEI: - UEI: -
Secondary Listings
RNXT has no secondary listings inside our databases.